Enoticumab manufacturers
- Enoticumab
-
- $795.00
-
2026-07-27
- CAS:1192578-27-0
- Purity: 98.2% (SDS-PAGE); 98.9% (SEC-HPLC)
- Supply Ability: 10g
|
| | Enoticumab Basic information |
| Product Name: | Enoticumab | | Synonyms: | Enoticumab;Research Grade Enoticumab (DHJ65302);Research Grade Enoticumab;Enoticumab (anti-DLL4) | | CAS: | 1192578-27-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Enoticumab Structure]() |
| | Enoticumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Enoticumab Usage And Synthesis |
| Uses | Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively[1]. | | References | [1] Kuhnert F, Chen G, Thurston G. Potent anti-tumor activity of blocking stromal Dll4 in ovarian xenograft models[J]. Cancer Research, 2013, 73(8_Supplement): 5091-5091. |
| | Enoticumab Preparation Products And Raw materials |
|